**Suspected Optic Neuritis/Neuropathy following administration of COVID-19 vaccine\***

Local Identification Number: Adverse Event Reference Number:

Patient Initials: Patient Age: Patient Sex:

Ethnicity:

|  |  |  |  |
| --- | --- | --- | --- |
| **Source of information** | | | |
| Name of the person reporting |  | Position (e.g. specialty and grade) |  |
| Hospital / Practice |  | Email address |  |

|  |  |
| --- | --- |
| **Patient Background** | |
| Past Medical History: | |
| Regular and recent medications: | |
| Infectious illness in the last six weeks: | Yes/ No/ Unsure |
| Other vaccination received in the last six weeks: | Yes/ No/ Unsure |
| Previous adverse neurological reaction to a vaccine: | Yes/ No/ Unsure |
| History of neurological disease (previous or current): | Yes/ No/ Unsure |
| Immunosupression at the time of vaccination: | Yes/ No/ Unsure |
| If Yes to any above, please provide details: | |

|  |  |
| --- | --- |
| **Patient’s Covid-19 Status** | |
| Previous diagnosis of Covid-19: | Yes, once/  Yes, more than once/ No/ Unsure |
| If Yes, date of onset: | Date: |
| If Yes, means of diagnosis: | PCR/ Antibody / Clinical |

|  |  |
| --- | --- |
| **Vaccination Details** | |
| 1st vaccination: Pfizer-BioNTech/ Oxford- AstraZeneca/ Moderna/ Sinopharm/ Sinovac/ Sputnik V/ Other- specify:  Lot number: \_\_\_\_\_ Dose: \_\_\_\_ Route of administration: | Date: |
| 2nd vaccination: Pfizer-BioNTech/ Oxford- AstraZeneca/ Moderna/ Sinopharm/ Sinovac/ Sputnik V/ Other- specify:  Lot number: \_\_\_\_\_ Dose: \_\_\_\_ Route of administration: | Date: |
| Date of neurological symptoms onset | Date: |

|  |  |
| --- | --- |
| **Case Definition** | |
| Acute visual disturbance secondary to optic nerve impairment | Yes/ No/ Unsure |
| PLUS Unknown Aetiology | Yes/ No/ Unsure |

|  |  |  |
| --- | --- | --- |
| **Clinical Features** | | |
| Time from onset to peak symptoms (hrs / days): | | |
| Select affected eye | R eye | L eye |
| Visual acuity | 6/\_\_\_\_/ counting fingers/ hand motion/ light perception/  no light perception | 6/\_\_\_\_/ counting fingers/ hand motion/ light perception/  no light perception |
| RAPD | Yes/ No/ Unsure | Yes/ No/ Unsure |
| Eye Pain | Yes/ No/ Unsure | Yes/ No/ Unsure |
| Loss of colour vision | Yes/ No/ Unsure | Yes/ No/ Unsure |
| Photopsia | Yes/ No/ Unsure | Yes/ No/ Unsure |
| Visual field defect- describe: |  |  |
| Fundoscopy/ slit lamp- describe: |  |  |
| Other relevant symptoms and signs, including other neurological deficits and systemic features: | | |
| Has the patient experienced a similar neurological event before? Yes/No/Unsure  If Yes, please provide details, including the date and suspected triggers: | | |

|  |  |
| --- | --- |
| **Assessment and investigations to exclude other causes** (please indicate which of the following have been considered, and give details at the bottom) | |
| **Clinical assessment** (give details at the bottom) | |
| Is there history of:   * Radiation to the brain or orbits * Exposure to medications or substances known to cause optic neuropathy | Yes/ No/ Unknown  Yes/ No/ Unknown |
| **Laboratory investigations** (if abnormal give details at the bottom) | |
| FBC  HbA1c  Lipid profile  CRP  ESR  ANA, anti-ds DNA, SS-A (Ro), SS-B (La), ANCA, complement  Anticardiolipin antibody, Lupus anticoagulant  B12, folate and methylmalonic acid  Thiamine (Vitamin B1)  Angiotensin converting enzyme  AQP-4 antibody  Syphilis serology  HIV serology  Lyme serology  COVID-19 serology/ PCR  QuantiFERON-TB or alternative | Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal |
| CSF Biochemistry:CSF Protein: \_\_\_\_\_\_\_ Serum:CSF Glucose Ratio: \_\_\_\_\_\_\_\_\_  CSF RCC: \_\_\_\_\_\_\_\_\_ CSF WCC: \_\_\_\_\_\_\_\_ CSF differential: \_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_ | |
| CSF Oligoclonal bands  CSF Cytology  CSF Microscopy & culture  CSF Virology\* | Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal |
| \*Please list the pathogens tested within the virology panel: | |
| Any other relevant laboratory results: | |
| **Radiological studies** (if abnormal give details at the bottom) | |
| MRI Head  MRI Optic Nerves  Optical Coherence Tomography  CXR/ CT Chest | Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal  Normal/ Unknown/ Not Done/ Abnormal |
| **Visual evoked potentials** | Normal/ Unknown/ Not Done/ Abnormal |
| **Genetic testing** | Normal/ Unknown/ Not Done/ Abnormal |
| **Details of any abnormal findings:** | |
| **Please describe if any of the findings could explain the aetiology of the event:** | |

|  |
| --- |
| **Treatment** (including dose and duration) |
|  |

|  |
| --- |
| **Patient outcome** |
| Date of last follow-up (if none, write none): |
| Maximum level of care required:  Outpatient/ Medical Inpatient/ High Dependency Unit/ Intensive Care Unit |
| Patient alive at last follow-up: Yes/ No  If No, was the optic neuritis included on the death certificate: Yes/ No/ Unknown  If relevant, date of death: |
| Outcome at least follow up (circle): Complete resolution / Incomplete resolution / No improvement / Re-occurrence / Other sequalae  If relevant, time to complete resolution:\_\_\_\_\_\_\_\_\_\_ |
| Modified Ranking Scale: Before adverse event:\_\_\_\_\_\_\_ At the last follow-up: \_\_\_\_\_\_ |
| Details: |

|  |  |
| --- | --- |
| **Subsequent COVID-19 Vaccinations** | |
| Has this patient received any further COVID-19 vaccines after the development of the neurological adverse event? | Yes/ No/ Unsure |
| If Yes: Pfizer-BioNTech/ Oxford- AstraZeneca/ Moderna/ Sinopharm/ Sinovac/ Sputnik V/ Other- specify:  Lot number: \_\_\_\_\_ Dose: \_\_\_\_ Route of administration: | Date: |
| If Yes, Outcome: No adverse event/ Re-occurrence of the same adverse event/ Development of another neurological adverse event/ Worsening of previously unresolved neurological adverse event/ Other sequelae  Date the outcome was last known: | |
| Other details: | |

\* This reporting form is based on Behbehani R. Clinical approach to optic neuropathies. Clinical Ophthalmology (Auckland, NZ). 2007 Sep;1(3):233.